Reduce freezing and improve walking
- Trial ID
- NCT06791902
- Official Title
- Study on Preliminary Safety and Efficacy of Adaptive DBS Aligned to Locomotor States to Improve Locomotor Functions in Parkinson's Patients
- Goal
- Reduce freezing and improve walking
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Jocelyne Bloch
- Study Type
- INTERVENTIONAL
- Enrollment
- 10 participants
- Conditions
- Parkinson Disease
- Interventions
- Adaptive DBS
Plain-Language Summary
The goal is to improve gait and balance problems in Parkinson's, for example reducing freezing of gait and making walking steadier. The approach uses adaptive deep brain stimulation with the implanted Medtronic Percept system, which reads local field potentials tied to walking and automatically adjusts stimulation in real time so the brain gets different patterns of stimulation during walking versus standing. It works alongside your current DBS device and Parkinson medications, targeting the specific brain rhythms linked to locomotion rather than delivering constant stimulation. The trial is looking for adults 18 and older who already have a full Medtronic Percept suite with bilateral leads, have gait or balance disorders with detectable LFP markers related to locomotion, can consent in French, and meet the study safety criteria.
Locations
- CHUV, Lausanne, Canton of Vaud, Switzerland
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Adaptive DBS. The goal is to improve gait and balance problems in Parkinson's, for example reducing freezing of gait and making walking steadier. The approach uses adaptive deep brain stimulation with the implanted Medtronic Percept system, which reads local field potentials tied to walking and automatically adjusts stimulation in real time so the brain gets different patterns of stimulation during walking versus standing. It works alongside your current DBS device and Parkinson medications, targeting the specific brain rhythms linked to locomotion rather than delivering constant stimulation. The trial is looking for adults 18 and older who already have a full Medtronic Percept suite with bilateral leads, have gait or balance disorders with detectable LFP markers related to locomotion, can consent in French, and meet the study safety criteria.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years.